Results 1 to 10 of about 22,830 (226)

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity [PDF]

Scientific Reports, 2017
ROS1 rearrangement is observed in 1–2% of non-small cell lung cancers (NSCLC). The ROS1 tyrosine kinase inhibitor (TKI) crizotinib has induced marked tumour shrinkage in ROS1-rearranged cancers.
Hayato Ogura, Yuka Nagatake-Kobayashi, Jun Adachi, Takeshi Tomonaga, Naoya Fujita, Ryohei Katayama   +5 more
doaj   +4 more sources

Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations [PDF]

JTO Clinical and Research Reports, 2021
Introduction: In this study, we sought to further characterize ROS1 protein expression in solid tumors with the complete spectrum of ROS1 genomic alterations. Methods: ROS1 immunohistochemistry (IHC) was performed using the ROS1 (SP384) class I assay per
Richard S.P. Huang, MD, Amanda Gottberg-Williams, BS, Panhia Vang, BS, Shoua Yang, HSD, Nicholas Britt, BS, Jaspreet Kaur, MS, James Haberberger, BS, Natalie Danziger, BS, Clarence Owens, BS, Sara E. Beckloff, PhD, Jeffrey S. Ross, MD, Shakti H. Ramkissoon, MD, PhD   +11 more
doaj   +3 more sources

Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib [PDF]

Frontiers in Medicine, 2021
ROS1 rearrangement, identified in ~2% of non-small cell lung cancer (NSCLC), has defined a distinctive molecular subtype. Patients with ROS1 fusion have been shown to be highly sensitive to treatment with crizotinib.
Long Xu, Xiaoxia Chen, Hong Huo, Yongye Liu, Xiaodan Yang, Dejian Gu, Mingming Yuan, Min Zhang, Min Zhang, Rongrong Chen, Jiayin Wang, Zhendong Zheng   +11 more
doaj   +3 more sources

In vitro and in silico modelling of ROS1-positive non-small cell lung cancer reveals fusion-dependent tyrosine kinase inhibitor responses. [PDF]

Mol Oncol
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Ul Haq F, Terrones M, Rodrigues Fortes F, Schepers A, Denis A, Deben C, Op de Beeck K, Van Camp G, Vandeweyer G.   +8 more
europepmc   +2 more sources

TET1 Inhibition Promotes Therapeutic Sensitivity in TP53-Mutant GBM by Influencing Genome Fragility and Altering TAMs Biology. [PDF]

Adv Sci (Weinh)
In TP53mut GBM cells, reduced P53 function is associated with increased TET1 expression. Genetic or pharmacological inhibition of TET1 correlates with genome fragility, including DNA damage, cellular senescence, telomere shortening, and reactive oxygen species accumulation, which may contribute to increased efficacy of antitumor therapy.
Pu Z, Liu J, Deng Y, Hao S, Zhang X, Yang M, Guo C, Du C, Chen Y, Sun T, Ji N, Zhuang Z, Feng J.   +12 more
europepmc   +2 more sources

Novel Pattern of Nuclear Staining With ROS1 Immunohistochemistry: A Case Report [PDF]

Case Reports in Pulmonology
ROS1 rearrangements are driver events in a subset of nonsmall cell lung carcinomas and may qualify patients for ROS1-directed treatment. ROS1 immunohistochemistry (IHC) is often used for screening of lung carcinomas for ROS1 gene rearrangement and has a ...
Diane M. Wilcock, Deepika Sirohi, Kristina Moore, Allie H. Grossmann, Georgios Deftereos   +4 more
doaj   +2 more sources

Structural insights into the activation of the chicken ROS1 receptor by the NEL/NICOL ligand complex [PDF]

Nature Communications
The receptor tyrosine kinase ROS1 plays essential roles in cell growth and sperm maturation, yet its activation mechanism has remained poorly understood. Here, we report high-resolution cryo-electron microscopy (cryo-EM) structures of chicken ROS1 in its
Weidong An, Xuewu Zhang, Xiao-chen Bai
doaj   +2 more sources

Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report

Case Reports in Oncology, 2023
Introduction: C-ros oncogene 1 (ROS1) translocation is an oncogenic driver-mutation identified in 1–2% of non-small-cell lung cancer (NSCLC) cases. Although crizotinib, a tyrosine kinase inhibitor (TKI) against ALK/ROS1, is known to be effective against ...
Hiromune Sawada, Yuri Taniguchi, Shin Iizuka, Toshiki Ikeda, Masaharu Aga, Yusuke Hamakawa, Kazuhito Miyazaki, Yuki Misumi, Yoko Agemi, Yukiko Nakamura, Koki Maeda, Tsuneo Shimokawa, Hiroaki Okamoto   +12 more
doaj   +1 more source

OPRM1-ROS1 Fusion Detected by Next-Generation Sequencing with Circulating DNA in a Patient with EGFR Mutated Advanced NSCLC: A Case Report

Case Reports in Oncology, 2022
ROS1 comprises a small molecular subset of NSCLC, and several fusion partners have been discovered. Concomitant mutations of EGFR and ROS1 in NSCLC have been occasionally reported, while no clear standard of treatment has been revealed.
Sicai Zhang, Zhiyong Xu, Weimin Zhang
doaj   +1 more source

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease

Drugs in Context, 2022
Oncogene addiction in non-small-cell lung cancer (NSCLC) has profound diagnostic and therapeutic implications. ALK, ROS1 and NTRK rearrangements are found in about 2–7%, 1–2% and 0.2% of unselected NSCLC samples, respectively; however, their frequency is
Daniele Marinelli, Marco Siringo, Giulio Metro, Biagio Ricciuti, Alain J Gelibter   +4 more
doaj   +1 more source